New cancer drug BLU-222 tested in early trial – but study stopped early
NCT ID NCT05252416
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a new drug called BLU-222, alone or with other medicines, in about 50 people with advanced solid tumors (including certain breast, ovarian, and stomach cancers). The goal was to find a safe dose and see if it shrinks tumors. However, the study was terminated early, so full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BLU-222 (a CDK2 inhibitor drug taken by mouth)
- What this could lead to
- If it works, this could point toward a new treatment option for certain advanced cancers, especially those with CCNE1 amplification.
- What could go wrong
- This is a very early (Phase 1/2) trial that was terminated, so results are limited. The drug may not be effective or safe in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University Herbert Irving Comprehensive Cancer Center
New York, New York, 10032, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Florida Cancer Specialists
Sarasota, Florida, 34232, United States
-
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, 20133, Italy
-
Fondazione Policlinico Universitario A Gemelli-Rome
Rome, 00168, Italy
-
Henry Ford Health System
Detroit, Michigan, 48202, United States
-
Hospital of the Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
-
Instituto Europeo di Oncologia
Milan, 20141, Italy
-
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center (SKCCC)
Baltimore, Maryland, 21287, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Montefiore Medical Center
New York, New York, 10461, United States
-
OU Health Stephenson Cancer Center
Oklahoma City, Oklahoma, 73104, United States
-
St Bartholomew's Hospital
London, Middlesex, EC1A 7BE, United Kingdom
-
Stanford Women's Cancer Center
Stanford, California, 94305, United States
-
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, 94158, United States
-
UNC Hospitals at Chapel Hill - The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27514, United States
-
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205, United States
-
University of Chicago Medical Center
Chicago, Illinois, 60637, United States
-
University of Utah - Huntsman Cancer Institute - PPDS
Salt Lake City, Utah, 84112, United States
-
University of Virginia Comprehensive Cancer Center
Charlottesville, Virginia, 22903, United States
-
Vanderbilt Breast Center at One Hundred Oaks
Nashville, Tennessee, 37204, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chest-Injected drug drain Cancer's fluid trap?
- A safer first cut? trial tests two laparoscopic entry points for endometrial cancer surgery
- Can a Three-Drug cocktail shrink stomach tumors before surgery?
- Could an AI-Designed pill take on Hard-to-Treat cancers?
- Can a new nucleotide analogue boost cancer treatment?
- Can a pill that blocks multiple cancer proteins shrink Hard-to-Treat tumors?